Research and new developments in pregnancy and arthritis
Our understanding of biological therapies and newer immunosuppressive drugs is growing. For instance, in the UK the British Society of Rheumatology (BSR) is gathering information on over 16,000 patients treated with adalimumab, etanercept and infliximab in a biologics registry (called the BSRBR) to examine the safety of these drugs.
Information from this registry on patients who continue taking these drugs while pregnant or breastfeeding will allow doctors to better determine their safety in these circumstances. There is, however, still an urgent need for studies clarifying the risk of anti-rheumatic drugs during breastfeeding and in men trying to father a child.